Novel strategy for rapid functional in vivo validation of oncogenic drivers in haematological malignancies-Reference-Cited by-同舟云学术

Novel strategy for rapid functional in vivo validation of oncogenic drivers in haematological malignancies

Published:2019-07-22 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Pieters Tim,T’Sas Sara,Demoen Lisa,Almeida André,Haenebalcke Lieven,Matthijssens Filip,Lemeire Kelly,D’Hont Jinke,Van Rockeghem Frederique,Hochepied Tino,Lintermans Beatrice,Reunes Lindy,Lammens Tim,Berx Geert^ORCID,Haigh Jody J.,Goossens Steven,Van Vlierberghe Pieter^ORCID

Funder

Fonds Baillet Latour

Flemish cancer society Stand up to Cancer Ghent University Special Research Fund (BOF) Belgian Foundation Against Cancer Research Foundation Flanders (FWO) Kinderkankerfonds

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-019-46853-x.pdf

Reference48 articles.

1. Friedrich, G. & Soriano, P. Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. Genes & development 5, 1513–1523 (1991).

2. Haenebalcke, L. et al. The ROSA26-iPSC mouse: a conditional, inducible, and exchangeable resource for studying cellular (De)differentiation. Cell Rep 3, 335–341 (2013).

3. Haenebalcke, L. et al. Efficient ROSA26-based conditional and/or inducible transgenesis using RMCE-compatible F1 hybrid mouse embryonic stem cells. Stem cell reviews 9, 774–785 (2013).

4. Nyabi, O. et al. Efficient mouse transgenesis using Gateway-compatible ROSA26 locus targeting vectors and F1 hybrid ES cells. Nucleic acids research 37, e55 (2009).

5. Pieters, T. et al. p120 Catenin-Mediated Stabilization of E-Cadherin Is Essential for Primitive Endoderm Specification. PLoS genetics 12, e1006243 (2016).

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tet2 is a tumor suppressor in the preleukemic phase of T-cell acute lymphoblastic leukemia;Blood Advances;2024-05-29

2. Myb overexpression synergizes with the loss of Pten and is a dependency factor and therapeutic target in T‐cell lymphoblastic leukemia;HemaSphere;2024-03

3. Myb drives B-cell neoplasms and myeloid malignancies in vivo;Blood Advances;2022-05-16

4. Direct and indirect anti-leukemic properties of Activity-on-Target interferons for the treatment of T-cell acute lymphoblastic leukemia;Haematologica;2021-10-14

5. Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice;Journal of Experimental Medicine;2021-08-18